logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Drugs

Results

Drugs

May 2021

Dostarlimab in addition to carboplatin and paclitaxel for recurrent or primary advanced endometrial cancer

Dostarlimab in addition to carboplatin and paclitaxel is in developmentfor recurrent or primary advanced endometrial cancer. Endometrial (uterine) cancer is cancer of the lining of the womb. Recurrent cancer is cancer that has come back after treatment. Advanced cancer is cancer that cannot normally be cured or controlled. Endometrial cancer is characterised by abnormal vaginal …

Drugs

May 2021

LAM-561 in addition to radiation therapy and temozolomide for glioblastoma –adjuvant

LAM-561 in addition to radiation therapy and temozolomide is in development as a treatment option for newly diagnosed glioblastoma patients. Glioblastoma is a fastgrowing brain tumour that develops from glial cells in the brain, is an aggressive brain cancer that typically results in death within months following diagnosis if not treated. Brain cancers are the …

Drugs

May 2021

Lenvatinib in combination with Pembrolizumab for advanced or recurrent endometrial cancer – First Line

Lenvatinib in combination with pembrolizumab is in clinical development for the treatment of advanced or recurrent endometrial cancer. Endometrial cancer is the most common form of womb cancer and originates from the lining of the womb (endometrium). The most common symptoms of this cancer are post-menopausal or irregular vaginal bleeding. Standard of care for patients …

Drugs

May 2021

Spesolimab for the treatment of acute flares of generalised pustular psoriasis

Spesolimab is currently in clinical development for the treatment of acute flares of generalised pustular psoriasis (GPP). Individuals with GPP experience repeated episodes where large surface areas of the skin become inflamed and red, and develop small pus-filled blisters known as pustules. It is a disease that spreads and affects a large surface area of …

Drugs

May 2021

Ripretinib for gastrointestinal stromal tumour

Ripretinib is currently in clinical development for the treatment of gastrointestinal stromal tumours (GIST). GIST is a rare type of cancer that commonly develops in the gastrointestinal tract. The cause of GIST is unknown, but most cases are associated with a certain gene mutation that produces abnormal enzymes. GIST are very aggressive, can spread quickly …

Drugs

May 2021

Dupilumab in addition to controller medications for children aged 6 to 11 years with asthma

Dupilumab is in clinical development as an add-on to controller medications for the maintenance treatment in children aged 6 to <12 years with uncontrolled, moderateto-severe asthma. Asthma is a common lung condition that causes wheezing, coughing and breathlessness. Individuals with asthma can suffer an asthma attack, which in severe cases can be fatal. Patients with …

Drugs

May 2021

Belimumab in combination with rituximab for systemic lupus erythematosus (SLE)

Belimumab in combination with a cycle of rituximab is in clinical development for adults with Systemic Lupus Erythematosus (SLE). SLE is an autoimmune disease where the body’s immune system attacks its own tissues and organs. Patients will often have periods where their symptoms flare-up and periods where their symptoms settle down. Mild SLE can cause …

Drugs

May 2021

Ganaxolone as adjuvant therapy for epilepsy with cyclin-dependent kinase-like 5 deficiency disorder

Ganaxolone is in development, as a novel treatment option for children and young adults with Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD). CDD is a debilitating disease that mainly manifests in children within a few months of birth. It affects the brain by impairing development, including the ability to learn speech and coordinate movement, and …

Drugs

May 2021

Conbercept for neovascular age-related macular degeneration

Conbercept is currently in clinical development for treatment of adults (≥ 50 years old) with Neovascular age-related macular degeneration (AMD), also known as wet AMD, a chronic eye disease. This disease is characterised by the formation of immature blood vessels that grow between the retina (macula; a layer of tissue in the back of the …

Drugs

May 2021

Etrolizumab for Crohn’s Disease

Etrolizumab is being developed for adults with moderate to severe Crohn’s disease (CD). CD is an inflammatory bowel disease (IBD) that can affect any part of the digestive system. It causes inflammation, which results in difficulty absorbing nutrients from food. Symptoms of moderate to severe CD include vomiting, abdominal pain, loss of weight, frequent diarrhoea, …

Get Alerts